Biopharmaceuticals
Oncology
News Release - October 18, 2011
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
Source: Halozyme Therapeutics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.